Table 5.
Median cost to patients of a pediatric dose (unit-dose packages specifically intended to treat a 2 year/10 kg child) formulation of quality-assured artemisinin combination therapies in remote areas and non-remote areas at the endline in Ghana and Kenya, in US dollars, 2011–2012
| Country/type of outlet | Remote areas | Non-remote areas | p value** | ||
|---|---|---|---|---|---|
| Median cost (IQR) | N | Median cost (IQR) | N | ||
| All QAACTs | |||||
| Ghana, total | 0.38 (0.31–0.63) | 50 | 0.63 (0.63–0.94) | 156 | 0.0102 |
| Public health facility | 0.28 (0.24–0.47) | 12 | 0.24 (0.24–0.47) | 5 | 0.7121 |
| Private not-for-profit health facilitya | – | 0 | 0.59 (0.24–0.94) | 2 | – |
| Private for-profit outlet | 0.63 (0.63–0.94) | 19 | 0.63 (0.63–0.94) | 149 | 0.7731 |
| Community health workera | 0.31 (0.31–0.38) | 19 | – | 0 | – |
| Kenya, Total | 0.00 (0.00–0.46) | 65 | 0.35 (0.00–0.46) | 254 | <0.0001 |
| Public health facility | 0.00 (0.00–0.00) | 27 | 0.00 (0.00–0.00) | 41 | – |
| Private not-for-profit health facilitya | 0.00 (0.00–0.23) | 10 | 0.00 (0.00–0.46) | 14 | 0.8642 |
| Private for-profit outlet | 0.46 (0.35–0.58) | 27 | 0.46 (0.35–0.46) | 199 | 0.2123 |
| Community health workera | 0.58 | 1 | – | 0 | – |
| QAACTs with AMFm logo | |||||
| Ghana, total | 0.63 (0.42–0.84) | 24 | 0.63 (0.63–0.94) | 147 | 0.4033 |
| Public health facility | 0.24 (0.24–0.47) | 7 | 0.24 (0.24–0.43) | 4 | 0.9041 |
| Private not-for-profit health facilitya | – | 0 | 0.59 (0.24–0.94) | 2 | – |
| Private for-profit outlet | 0.63 (0.63–0.94) | 17 | 0.63 (0.63–0.94) | 141 | 0.8613 |
| Community health workera | – | 0 | – | 0 | – |
| Kenya, total | 0.00 (0.00–0.46) | 52 | 0.35 (0.23–0.46) | 212 | <0.0001 |
| Public health facility | 0.00 (0.00–0.00) | 21 | 0.00 (0.00–0.00) | 19 | 0.4845 |
| Private not-for-profit health facilitya | 0.00 (0.00–0.00) | 4 | 0.00 (0.00–0.58) | 6 | 0.7213 |
| Private for-profit outlet | 0.46 (0.35–0.58) | 26 | 0.46 (0.35–0.46) | 187 | 0.2731 |
| Community health workera | 0.58 | 1 | – | 0 | – |
IQR interquartile range, N number of products, AMFm affordable medicine facility-malaria
** p value for Wilcoxon rank sum test for difference between remote and non-remote areas
aThese are presented in the table because they contribute to the country overall estimates; however, they are not discussed in the text because of the small sample